CELLECT BIOTECH/S (APOP) Shares Down 3.8%
CELLECT BIOTECH/S (NASDAQ:APOP)’s share price was down 3.8% during trading on Wednesday . The company traded as low as $1.05 and last traded at $1.02. Approximately 4,276 shares traded hands during trading, a decline of 99% from the average daily volume of 369,235 shares. The stock had previously closed at $1.06.
A number of equities analysts recently commented on APOP shares. HC Wainwright set a $12.00 price target on shares of CELLECT BIOTECH/S and gave the stock a “buy” rating in a research note on Wednesday, December 12th. Zacks Investment Research raised shares of CELLECT BIOTECH/S from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Thursday, January 3rd.
The stock has a market cap of $5.60 million, a PE ratio of -0.70 and a beta of 2.43.
CELLECT BIOTECH/S Company Profile (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Read More: How to invest in a bear market
Receive News & Ratings for CELLECT BIOTECH/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELLECT BIOTECH/S and related companies with MarketBeat.com's FREE daily email newsletter.